Nuritas is a drug discovery company that uses Artificial Intelligence (AI) and Machine Learning to accelerate the identification and validation of bioactive peptide drug candidates across multiple therapeutic areas, with incredible speed. Nuritas' platform takes only months to deliver molecules that have a high success rate (>60% predicted). This is due to our advanced AI platform for targeting, validating, and unlocking those molecules, all which are done in house (in silico and wet lab validation). Nuritas is the first company in the world to prove AI can take a healthcare product from concept to market, and we did it in less than 2 years (in partnership with BASF).
We are currently addressing several indications across multiple therapeutic areas, including inflammation, diabetes, hypertension, and anti-microbials. Efforts to expand into other therapeutic areas including oncology and undruggable targets continue, both internally, and through external collaborations. Nuritas is privately funded with more than $60M raised in 4 years. The science and AI is now validated, with more than 1,000,000 novel peptides discovered in 2018 alone, 2,000 of which are under patent. We seek co-development and funded collaborations with pharma and look forward to progressing a dialog with you.
State of Ownership